Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNA-120 (Pegcantratinib) in Pruritus and Psoriasis
NCT03448081Phase 2Completed
- Sponsor
- Sienna Biopharmaceuticals
- Start
- Feb 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in pruritus and psoriasis comparing SNA-120 + Calcipotriene with Placebo + Calcipotriene (2 arms). Primary endpoint: Change in Itch Numeric Rating Scale scores at 8 weeks. Started Feb 2018; status: completed.
02
Drugs
pegcantratinib
03
Conditions
prurituspsoriasis
Beyond the preview
Go deeper on NCT03448081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03448081.